Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen

Journal of the National Cancer Institute

Volumn 91, Issue 2, 1999, Pages 169-175

  Xie, Yilin C ^a   Hwang, C ^a   Overwijk, Willem ^c   Zeng, Zhi ^a   Eng, Marvin H ^a   Mule J J ^a   Imperiale, M J ^b   Restifo, N P ^c   Sanda, M G ^d  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; M TAG VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENETIC RECOMBINATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; TUMOR IMMUNOLOGY; VACCINATION; VIRUS CARCINOGENESIS;

EID: 0033585482     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.2.169     Document Type: Article

References (35)

1. Carbone M, Rizzo P, Procopio A, Giuliano M, Pass HI, Gebhardt MC, et al. SV40-like sequences in human bone tumors. Oncogene 1996;13:527-35.
2. Bergsagel DJ, Finegold MJ, Butel JS, Kupsky WJ, Garcea RL. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 1992;326:988-93.
3. Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, Mew DJ, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994;9:1781-90.
4. Lednicky JA, Garcea RL, Bergsagel DJ, Butel JS. Natural simian virus 40 strains are present in choroid plexus and ependymoma tumors. Virology 1995;212:710-7.
5. Geissler E. SV40 and human brain tumors. Prog Med Virol 1990;37:211-22.
6. De Luca A, Baldi A, Esposito V, Howard CM, Bagella L, Rizzo P, et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nature Med 1997;3:913-6.
7. Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJ, Shridhar V, et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 1997;3:908-12.
8. Shah K, Nathanson N, Human exposure to SV40: review and comment. Am J Epidemiol 1976;103:1-12.
9. Carbone M, Rizzo P, Pass HI. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 1997;15: 1877-88.
10. Bright RK, Beames B, Shearer MH, Kennedy RC. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res 1996;56:1126-30.
11. Gooding LR, O'Connell KA. Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen. J Immunol 1983;131:2580-6.
12. Knowles BB, Koncar M, Pfizenmaier K, Solter D, Aden DP, Trinchieri G. Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen. J Immunol 1979; 122:1798-806.
13. Tevethia SS. Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. Mol Biol Med 1990;7:83-96.
14. Earl PL, Cooper N, Moss B. Preparation of cell cultures and vaccinia virus stocks. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith LA, et al, editors. Current protocols in molecular biology. Vol 2. New York (NY): Greene Publishing Associates and Wiley Interscience; 1991. p. 16.16.1-16.16.7.
15. Bronte V, Tsung K, Rao JB, Chen PW. Wang M, Rosenberg SA, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
16. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A 1997;94:3183-8.
17. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-5.
18. Zhu J, Rice PW, Gorsch L, Abate M, Cole CN. Transformation of a continuous rat embryo fibroblast cell line requires three separate domains of simian virus 40 large T antigen. J Virol 1992;66:2780-91.
19. Peden KW, Spence SL, Tack LC, Cartwright CA, Srinivasan A, Pipas JM. A DNA replication-positive mutant of simian virus 40 that is defective for transformation and the production of infectious virions. J Virol 1990;64:2912-21.
20. Pipas JM, Peden KW, Nathans D. Mutational analysis of simian virus 40 T antigen: isolation and characterization of mutants with deletions in the T-antigen gene. Mol Cell Biol 1983;3: 203-13.
21. Stubdal H, Zalvide J, DeCaprio JA. Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. J Virol 1996;70:2781-8.
22. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152: 163-75.
23. Parker KC. HLA peptide binding predictions software [computer program]. Bethesda (MD): National Cancer Institute, 1998 (http:// bimas.dcrt.nih.gov/cgi-bin/molbio/ken-parker-comboform).
24. Earl PL, Hugin AW, Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol 1990;64:2448-51.
25. Mole SE, Cannon JV, Anton IA, Ford MJ, Lane DP. Host proteins that bind to or mimic SV40 large T antigen: using antibodies to look at protein interactions and their significance. Immunol Suppl 1989:2:80-5.
26. Anderson JL, Martin RG, Chang C, Mora PT, Livingston DM. Nuclear preparations of SV40-transformed cells contain tumor-specific transplantation antigen activity. Virology 1977;76: 420-5.
27. Bright RK, Shearer MH, Kennedy RC. SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice. Mol Immunol 1994;31:1077-87.
28. Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, et al. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol 1998;72:1469-81.
29. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991;252: 1662-7.
30. Borysiewicz KL, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
31. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991; 181:62-9.
32. Lathe R, Kieny MP, Gerlinger P, Clertant P, Guizani I, Cuzin F, et al. Tumor prevention and rejection with recombinant vaccinia. Nature 1987;326:878-80.
33. Lee TD. Distribution of HLA antigens in North American Caucasians, North American blacks, and Orientals. In: Lee J, editor. The HLA system: a new approach. New York (NY): Springer-Verlag; 1990.
34. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class 1 molecules depends on the MHC-peptide complex stability. J Immunol 1996;156:3308-14.
35. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, et al. A multiinstitutional study confirms the presence and expression of Simian Virus 40 in human malignant mesotheliomas. Cancer Res 1998;58: 4505-9.